Cantor Fitzgerald Reiterates Overweight Rating on Vanda Pharmaceuticals (VNDA)
Tweet Send to a Friend
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating and $13.00 price target on Vanda Pharmaceuticals (NASDAQ: VNDA).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
